The Dog That Didn’t Bark: ODAC Gives Nod To Three Products Despite Negative FDA Reviews

 
• By Sue Sutter

Oncologic Drugs Advisory Committee was swayed by views of its disease area experts in favorably reporting out Geron’s imetelstat for myelodysplastic syndromes and supplemental applications for the CAR-T products Carvykti and Abecma in earlier lines of multiple myeloma.

Dogs barking
Even though FDA briefing documents were skeptical, the proverbial dog did not bark at ODAC, where three drugs had a smooth passage. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers